| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/06/2007 | CN1973823A Anticancer composition containing Synergist |
| 06/06/2007 | CN1973822A Anticancer composition containing Sirolimus |
| 06/06/2007 | CN1973821A Medicine composition containing both anticancer medicine and its synergist |
| 06/06/2007 | CN1973820A Anticancer composition containing Sirolimus and its application |
| 06/06/2007 | CN1973819A Anticancer composition containing anticancer medicine and its synergist |
| 06/06/2007 | CN1973818A Solid tumor treating medicine composition |
| 06/06/2007 | CN1973817A Solid tumor treating slow releasing prepn containing chemotherapy synergist |
| 06/06/2007 | CN1319968C Compositions useful as inhibitors of GSK-3 |
| 06/06/2007 | CN1319938C Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| 06/06/2007 | CN1319540C Use of fucans in the treatment of adhesions, arthritis and psoriasis |
| 06/05/2007 | US7227033 Crystalline polymorph of the anhydrous form in synergistic combination with another active ingredient to enhance drug delivery; antidiabetic agents |
| 06/05/2007 | US7226946 Substituted phenol compounds useful for anesthesia and sedation |
| 06/05/2007 | US7226943 Antilipemic agents |
| 06/05/2007 | US7226937 Methods for modulating phototoxicity |
| 06/05/2007 | US7226934 Having antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen |
| 06/05/2007 | US7226928 Methods for the treatment of periodontal disease |
| 06/05/2007 | US7226916 For oral administration of a preparation having a) long chain polyunsaturated fatty acids, and b) specified phospholipids, and c) compounds that factor in methionine metabolism, such as folate, B vitamins, magnesium and zinc |
| 06/05/2007 | US7226910 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists |
| 06/05/2007 | US7226604 Chemically inactivated EHV-1 KyA virus; and an adjuvant which includes cross-linked olefinically unsaturated carboxylic acid polymer |
| 06/05/2007 | US7226596 Metalloenzymes; antiproliferative agents; anticarcinogenic agents; cancer diagnosis; antisense agents; complementary determining regions |
| 06/05/2007 | CA2294385C Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 06/05/2007 | CA2273823C Polypeptides encoded by a human lipase-like gene, compositions and methods |
| 06/05/2007 | CA2237335C The use of cholinesterase inhibitors in the treatment of xerostomia |
| 06/05/2007 | CA2181165C Anti-fungal methods and materials |
| 05/31/2007 | WO2007062198A1 Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| 05/31/2007 | WO2007062093A2 Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
| 05/31/2007 | WO2007061874A2 Methods and compositions for use in treating cancer |
| 05/31/2007 | WO2007061868A2 Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| 05/31/2007 | WO2007061114A1 Pharmaceutical composition for prevention or treatment of neurogenic pain |
| 05/31/2007 | WO2007061094A1 Pharmaceutical comprising ppar agonist |
| 05/31/2007 | WO2007061029A1 Therapeutic agent for prostate cancer |
| 05/31/2007 | WO2007061022A1 Mitochondrial function of prohibitin 2 (phb2) |
| 05/31/2007 | WO2007060918A1 Novel memory ctl induction potentiator |
| 05/31/2007 | WO2007060899A1 Application of actin-binding protein to disease associated with cell motility |
| 05/31/2007 | WO2007060419A2 Method of preventing oral staining |
| 05/31/2007 | WO2007060382A1 Cell aggregates |
| 05/31/2007 | WO2007060038A2 Preparation, comprising iron(iii) complex compounds and redox-active substances |
| 05/31/2007 | WO2007059762A1 Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide |
| 05/31/2007 | WO2007037560A9 Therapeutic or diagnostic application of sgk2 gene |
| 05/31/2007 | WO2007037555A9 Therapeutic or diagnostic application of dusp15 gene |
| 05/31/2007 | WO2007037550A9 Therapeutic or diagnostic application of tsta3 gene |
| 05/31/2007 | WO2007037543A9 Biarylamide derivative |
| 05/31/2007 | WO2007037538A9 Therapeutic or diagnostic application of spo11 gene |
| 05/31/2007 | WO2007037533A9 Therapeutic or diagnostic application of ppp1r3d gene |
| 05/31/2007 | WO2007037532A9 Therapeutic or diagnostic application of srms gene |
| 05/31/2007 | WO2007019549A3 Composition and method for use in cartilage affecting conditions |
| 05/31/2007 | WO2007010498A3 Compositions for reducing the incidence of drug induced arrhythmia |
| 05/31/2007 | WO2006110491B1 Complementary compositions to reduce blood glucose levels and treat diabetes |
| 05/31/2007 | WO2006073981A3 Regulation of microphage migration inhibitory factor (mif) activity |
| 05/31/2007 | WO2006067312A3 Painkilling association comprising a dihydroimidazopyrazine derivative |
| 05/31/2007 | WO2005077005A3 Enhancing the effectiveness of an inhaled therapeutic gas |
| 05/31/2007 | US20070124825 Use of hepcidin as a regulator of iron homeostasis |
| 05/31/2007 | US20070124083 Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| 05/31/2007 | US20070123580 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 05/31/2007 | US20070123518 Product designed to protentiate the therapeutic effects and to enhance the action of medicinal preparations |
| 05/31/2007 | US20070123517 Pharmacological treatment for sleep apnea |
| 05/31/2007 | US20070123498 Combination of organic compounds |
| 05/31/2007 | US20070123488 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis |
| 05/31/2007 | US20070123470 Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue |
| 05/31/2007 | US20070123459 IL-17 like molecules and uses thereof |
| 05/31/2007 | US20070122860 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 05/31/2007 | US20070122490 Wound healing compound |
| 05/31/2007 | US20070122475 Taste masking composition |
| 05/31/2007 | US20070122474 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 05/31/2007 | US20070122452 Fat composition |
| 05/31/2007 | US20070122412 Eg-vegf nucleic acids and polypeptides and methods of use |
| 05/31/2007 | US20070122399 Nutraceutical formulation for healing human bone due to accidental fracture or surgical replacement or grafting, containing lysine, proline, ascorbic acid, copper, and vitamin B6 |
| 05/31/2007 | US20070122394 administering a VEGFR modulating agent that comprises placental growth factor; a growth factor that binds and activates Flt-1 such as PIGF or VEGF-B, an anti-Flt-1 agonistic antibody or a small molecule agonist |
| 05/31/2007 | US20070122370 Compositions comprising oligoglycosides |
| 05/31/2007 | US20070122352 Inhalation Drug Combinations |
| 05/31/2007 | US20070122351 Inhalation Drug Combinations |
| 05/31/2007 | US20070122348 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject |
| 05/31/2007 | DE69133083C5 Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten Treatment and prevention mediated by elevated lyso-PAF mirror mental disorders with PAF antagonists |
| 05/31/2007 | DE102005047616A1 Kombination Combination |
| 05/31/2007 | CA2630818A1 Pharmaceutical composition for prevention or treatment of neurogenic pain |
| 05/31/2007 | CA2630816A1 Pharmaceutical comprising ppar agonist |
| 05/30/2007 | EP1790983A1 Method of screening compound preventing cells from infection with hepatitis c virus (hcv) |
| 05/30/2007 | EP1790730A2 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 05/30/2007 | EP1790729A2 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 05/30/2007 | EP1790728A2 Imaging, diagnosis and treatment of disease |
| 05/30/2007 | EP1790717A2 Compositions and methods for the identification of lung tumor cells |
| 05/30/2007 | EP1790652A1 Polycyclic guanine phosphodiesterase V inhibitors |
| 05/30/2007 | EP1790639A1 Compound containing basic group and use thereof |
| 05/30/2007 | EP1790637A1 Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| 05/30/2007 | EP1790357A2 Perorally administrable antimicrobial composition |
| 05/30/2007 | EP1790356A1 Preparation containing iron(III)-complexes and redox substances |
| 05/30/2007 | EP1790355A1 Propagation agent and propagation method for natural killer cell |
| 05/30/2007 | EP1790353A1 Combined use of a GLP-1 compound and a modulator of diabetic late complications |
| 05/30/2007 | EP1790340A2 Combination chemotherapy |
| 05/30/2007 | EP1790339A1 Composition for prevention of occurrence of cardiovascular event |
| 05/30/2007 | EP1790223A1 Organ arrest, protection and preservation |
| 05/30/2007 | EP1790220A1 Pathologic model animal for non-alcoholic fatty hepatitis |
| 05/30/2007 | EP1789433A2 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 05/30/2007 | EP1789107A2 Medical stent provided with inhibitors of atp synthesis |
| 05/30/2007 | EP1789090A2 Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors |
| 05/30/2007 | EP1789088A2 Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods |
| 05/30/2007 | EP1789077A2 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 05/30/2007 | EP1789051A1 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
| 05/30/2007 | EP1789046A2 Peripheral benzodiazepine receptor independent superoxide generation |
| 05/30/2007 | EP1789030A2 Medical implant provided with inhibitors of atp synthesis |